The National Health Service in England has approved a groundbreaking new therapy that can delay the onset of type 1 diabetes for up to three years, marking what experts are calling the start of a new era in treatment. The drug, teplizumab, also known by the brand name Tzield, is the first of its kind to target the root cause of the condition rather than simply managing its symptoms.
Teplizumab is approved for children aged eight and older and adults who are in the early stages of type 1 diabetes, before symptoms appear. It is administered as a one-off course through a drip into a vein once a day for 14 consecutive days, with the dose starting low and gradually increasing. The therapy works by training the immune system to stop attacking the insulin-producing cells in the pancreas. The National Institute for Health and Care Excellence estimates that around 1,100 people will be eligible for the treatment in the first year, with that number settling to approximately 820 patients in subsequent years.
For patients and families, the impact is deeply personal. One mother whose nine-year-old son received teplizumab after being identified through a screening study described the drug as giving her child “time” to be a child without daily insulin injections and carbohydrate counting. The treatment does not cure type 1 diabetes, but it offers a critical window of freedom from the relentless demands of managing the condition. Diabetes UK called the approval a “landmark moment” and said it represents a shift toward a future where type 1 diabetes could one day be prevented altogether.
Early Detection Is Key to Unlocking the Benefits
For teplizumab to work, patients must be identified early, before symptoms like excessive thirst, weight loss, and fatigue appear. Two major screening studies are currently underway in the UK. The Elsa study, funded by Diabetes UK and Breakthrough T1D, is screening children aged two to 17. The separate T1DRA study is screening adults between 18 and 70. These programs aim to find people with early-stage type 1 diabetes so they can be offered teplizumab and potentially gain years of symptom-free life.
Experts are hopeful that this approval is just the beginning. Researchers are working toward a national type 1 diabetes screening program that would identify thousands more people in the early stages of the disease. As one director at the National Institute for Health and Care Excellence put it, this recommendation is “genuinely exciting” because it offers patients precious extra time before they need to manage the full burden of the condition. For the first time in a century, the focus has shifted from simply replacing insulin to changing the course of the disease itself.